AR117621A2 - UNA SOLUCIÓN ACUOSA SIN ALCOHOL ETÍLICO QUE COMPRENDE UN b-BLOQUEANTE Y DISPOSITIVO - Google Patents

UNA SOLUCIÓN ACUOSA SIN ALCOHOL ETÍLICO QUE COMPRENDE UN b-BLOQUEANTE Y DISPOSITIVO

Info

Publication number
AR117621A2
AR117621A2 ARP190102095A ARP190102095A AR117621A2 AR 117621 A2 AR117621 A2 AR 117621A2 AR P190102095 A ARP190102095 A AR P190102095A AR P190102095 A ARP190102095 A AR P190102095A AR 117621 A2 AR117621 A2 AR 117621A2
Authority
AR
Argentina
Prior art keywords
blocker
aqueous solution
ethyl alcohol
alcohol including
propranolol
Prior art date
Application number
ARP190102095A
Other languages
English (en)
Original Assignee
Pierre Fabre Dermatologie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40940328&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR117621(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pierre Fabre Dermatologie filed Critical Pierre Fabre Dermatologie
Publication of AR117621A2 publication Critical patent/AR117621A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Seasonings (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Una solución acuosa sin alcohol etílico, que comprende un b-bloqueante, un edulcorante de tipo no azucarado y que está sustancialmente libre de un agente conservante aromático. Él se selecciona de un b-bloqueante no selectivo, por ejemplo de alprenolol, bucindolol, carteolol, carvedilol, labetalol, levobunolol, medroxalol, mepindolol, metipranolol, nadolol, oxprenolol, penbutolol, pindolol, propafenona, propranolol, sotalol, timolol y sales farmacéuticamente aceptables de los mismos y, por ejemplo, propranolol o una sal farmacéuticamente aceptable del mismo, y está presente en una cantidad de 0,001 a 5% p/V, por ejemplo de 0,01 a 1% p/V.
ARP190102095A 2009-04-21 2019-07-25 UNA SOLUCIÓN ACUOSA SIN ALCOHOL ETÍLICO QUE COMPRENDE UN b-BLOQUEANTE Y DISPOSITIVO AR117621A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09290298A EP2246044A1 (en) 2009-04-21 2009-04-21 Paediatric solutions comprising a beta-blocker

Publications (1)

Publication Number Publication Date
AR117621A2 true AR117621A2 (es) 2021-08-18

Family

ID=40940328

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP100101299A AR076338A1 (es) 2009-04-21 2010-04-20 Disoluciones pediatricas para beta-bloqueantes
ARP190102095A AR117621A2 (es) 2009-04-21 2019-07-25 UNA SOLUCIÓN ACUOSA SIN ALCOHOL ETÍLICO QUE COMPRENDE UN b-BLOQUEANTE Y DISPOSITIVO

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP100101299A AR076338A1 (es) 2009-04-21 2010-04-20 Disoluciones pediatricas para beta-bloqueantes

Country Status (32)

Country Link
US (2) US20120035270A1 (es)
EP (4) EP2246044A1 (es)
JP (1) JP5695029B2 (es)
KR (1) KR101713866B1 (es)
CN (1) CN102405041A (es)
AR (2) AR076338A1 (es)
AU (1) AU2010240551B2 (es)
BR (1) BRPI1015447B1 (es)
CA (1) CA2755175C (es)
CL (1) CL2011002634A1 (es)
CO (1) CO6410278A2 (es)
CY (2) CY1119390T1 (es)
DK (2) DK2421504T4 (es)
ES (2) ES2623936T5 (es)
GE (1) GEP20146087B (es)
HR (2) HRP20170610T4 (es)
HU (2) HUE034581T2 (es)
IL (1) IL214674A (es)
LT (2) LT2497461T (es)
MA (1) MA33003B1 (es)
MX (1) MX337463B (es)
NZ (1) NZ594592A (es)
PL (2) PL2497461T5 (es)
PT (2) PT2421504T (es)
RS (2) RS57668B2 (es)
RU (1) RU2011139233A (es)
SG (1) SG172960A1 (es)
SI (2) SI2421504T1 (es)
TN (1) TN2011000350A1 (es)
TW (1) TWI429459B (es)
UA (1) UA107570C2 (es)
WO (1) WO2010122442A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2246044A1 (en) 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Paediatric solutions comprising a beta-blocker
HUE027514T2 (en) * 2011-03-04 2016-10-28 Gruenenthal Gmbh Parenteral administration of tapentadol
JP2019142972A (ja) * 2011-03-04 2019-08-29 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールの非経口的投与
PT2680832T (pt) 2011-03-04 2019-10-28 Gruenenthal Gmbh Formulação farmacêutica aquosa de tapentadol para administração oral
US9724297B2 (en) 2014-04-01 2017-08-08 Arbor Pharmaceuticals, Inc. Sotalol compositions and uses of the same
PT3479823T (pt) 2015-03-27 2020-09-29 Gruenenthal Gmbh Formulação estável para administração parentérica de tapentadol
MX2019003257A (es) 2016-09-23 2019-06-10 Gruenenthal Gmbh Formulacion estable para la administracion parenteral de tapentadol.
CN108261411B (zh) * 2016-12-30 2021-04-30 武汉科福新药有限责任公司 用于婴幼儿血管瘤治疗的口腔膜剂及其制备方法
CN107320467A (zh) * 2017-07-21 2017-11-07 江苏云阳集团药业有限公司 一种盐酸普萘洛尔药用组合物及其制备方法
CN108299279B (zh) * 2018-02-09 2021-03-23 北京梅尔森医药技术开发有限公司 取代芳基胺醇化合物及其制备方法和用途
US11547123B2 (en) * 2019-08-16 2023-01-10 The Folger Coffee Company Methods for reducing negative flavor attributes in coffee and compositions therefrom
CN116472036A (zh) 2020-09-30 2023-07-21 日产化学株式会社 包含水溶性β阻断剂及卵磷脂的复合体

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4600708A (en) 1985-07-19 1986-07-15 American Home Products Corporation Propranolol hydrochloride liquid formulations
HU209251B (en) 1992-03-13 1994-04-28 Synepos Ag Process for producing stable, peroral solution drug forms with controlled release of active ingredient and comprising beta-blocking pharmacons
DE69613164T2 (de) 1995-03-15 2001-09-27 Kao Corp Verwendung eines Zusatzstoffes zur Verminderung von Bittergeschmack
JPH1025253A (ja) * 1996-07-12 1998-01-27 Kao Corp 苦味低減化剤及び苦味低減化法
JPH11349492A (ja) * 1998-06-03 1999-12-21 Yamanouchi Pharmaceut Co Ltd 苦味を低減した経口用医薬組成物および苦味低減化方法
JP2001342151A (ja) * 2000-03-31 2001-12-11 Eisai Co Ltd 甘味を有する薬剤組成物
CZ299755B6 (cs) * 2001-05-25 2008-11-12 Warner-Lambert Company Llc Kapalná farmaceutická kompozice obsahující analoggama-aminomáselné kyseliny, zpusob její prípravy a použití
EP1543831A1 (en) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Pregabalin composition
EP1850854A1 (en) * 2005-02-25 2007-11-07 Biomarin Pharmaceutical Inc. Room temperature stable aqueous liquid pharmaceutical composition
MX2007014713A (es) * 2005-05-25 2008-02-14 Janssen Pharmaceutica Nv Formulacion pediatrica de topiramato.
DE102006020604A1 (de) * 2006-05-02 2007-11-08 Bayer Healthcare Ag Flüssige Arzneimittelformulierung
EP2050441A1 (en) 2007-10-19 2009-04-22 Université Victor Segalen Bordeaux 2 Use of beta blocker for the manufacture of a medicament for the treatment of hemangiomas
CA2722393A1 (en) * 2008-04-25 2009-10-29 Apotex Technologies Inc. Liquid formulation for deferiprone with palatable taste
EP2246044A1 (en) 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Paediatric solutions comprising a beta-blocker

Also Published As

Publication number Publication date
LT2497461T (lt) 2018-10-10
SI2497461T2 (sl) 2022-04-29
GEP20146087B (en) 2014-05-13
UA107570C2 (xx) 2015-01-26
TN2011000350A1 (en) 2013-03-27
SG172960A1 (en) 2011-08-29
BRPI1015447A8 (pt) 2017-10-03
EP2497461B1 (en) 2018-06-20
PT2497461T (pt) 2018-10-23
CO6410278A2 (es) 2012-03-30
KR20120015305A (ko) 2012-02-21
TW201039862A (en) 2010-11-16
PT2421504T (pt) 2017-06-16
EP2421504A1 (en) 2012-02-29
DK2497461T3 (en) 2018-09-03
RS57668B2 (sr) 2022-03-31
PL2497461T3 (pl) 2018-12-31
CN102405041A (zh) 2012-04-04
IL214674A (en) 2017-01-31
AR076338A1 (es) 2011-06-01
BRPI1015447B1 (pt) 2020-01-28
EP3384899A1 (en) 2018-10-10
AU2010240551A1 (en) 2011-08-04
MA33003B1 (fr) 2012-01-02
PL2497461T5 (pl) 2022-06-27
HRP20181408T4 (hr) 2022-03-04
RS55862B1 (sr) 2017-08-31
SI2497461T1 (sl) 2018-10-30
HRP20170610T4 (hr) 2022-12-09
CY1119390T1 (el) 2018-02-14
CY1120667T1 (el) 2019-12-11
EP2421504B2 (en) 2022-08-10
EP2497461B2 (en) 2021-12-15
KR101713866B1 (ko) 2017-03-09
BRPI1015447A2 (pt) 2016-04-19
ES2685178T5 (es) 2022-04-13
MX2011010766A (es) 2011-10-21
HUE034581T2 (en) 2018-02-28
TWI429459B (zh) 2014-03-11
JP2012524773A (ja) 2012-10-18
RS57668B1 (sr) 2018-11-30
EP2497461A3 (en) 2014-01-01
NZ594592A (en) 2013-11-29
HRP20181408T1 (hr) 2018-11-02
JP5695029B2 (ja) 2015-04-01
RS55862B2 (sr) 2022-12-30
CL2011002634A1 (es) 2012-06-08
PL2421504T3 (pl) 2017-08-31
LT2421504T (lt) 2017-06-12
ES2685178T3 (es) 2018-10-05
RU2011139233A (ru) 2013-05-27
HUE039937T2 (hu) 2019-02-28
EP2421504B1 (en) 2017-03-08
EP2246044A1 (en) 2010-11-03
EP2497461A2 (en) 2012-09-12
CA2755175A1 (en) 2010-10-28
US20150087719A1 (en) 2015-03-26
ES2623936T5 (es) 2022-11-28
PL2421504T5 (pl) 2023-01-02
HRP20170610T1 (hr) 2017-07-28
AU2010240551B2 (en) 2015-07-16
DK2421504T4 (da) 2022-11-14
IL214674A0 (en) 2011-09-27
ES2623936T3 (es) 2017-07-12
US20120035270A1 (en) 2012-02-09
DK2421504T3 (en) 2017-05-01
SI2421504T1 (sl) 2017-06-30
MX337463B (es) 2016-03-07
WO2010122442A1 (en) 2010-10-28
DK2497461T4 (da) 2022-02-14
CA2755175C (en) 2018-01-02

Similar Documents

Publication Publication Date Title
AR117621A2 (es) UNA SOLUCIÓN ACUOSA SIN ALCOHOL ETÍLICO QUE COMPRENDE UN b-BLOQUEANTE Y DISPOSITIVO
CO6270209A2 (es) Un beta bloqueante para el tratamiento de los hemangiomas
ES2510565T3 (es) Envase de ajuste de dosis para neramexano y su uso en el tratamiento de un trastorno del oído interno
ES2537539T3 (es) Composición oftálmica
CY1122516T1 (el) Ετοιμες προς χρηση διατυπωσεις κετορολακης
UY30056A1 (es) Administracion transdermica de meptazinol
CR9737A (es) Dispositivos de administracion transdermicas de farmacos que contienen o-desmetilvenlafaxina (odv) sus sales.
ECSP11011016A (es) Formas de dosificación del tapentadol novedosas y potentes
GT200800143A (es) Derivados de pirimidina utilizados como inhibidores de cinasa pi-3
PE20142372A1 (es) Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico
ECSP067068A (es) DERIVADOS DE AMINO-5,5-DIFENILIMIDAZOLONA PARA LA INHIBICIÓN DE b-SECRETASA
GT201200247A (es) Formulaciones orales y sales lipofílicas de metilnaltrexona
PE20060257A1 (es) Composicion farmaceutica de flibanserina para el tratamiento de trastornos premestruales y otros trastornos sexuales femeninos
ECSP067080A (es) DIFENILIMIDAZOPIRIMIDINA Y AMINAS IMIDAZOL COMO INHIBIDORES DE ß-SECRETASA
AR083395A1 (es) Derivado peptidico nmu (neuromedina u) con elevado efecto anorectico
ES2570599T3 (es) Composición suave para desinfección cutánea
CR20120353A (es) Método de tratamiento de la fibrilación auricular
UY30901A (es) Nuevos metodos
BRPI0916540B8 (pt) inibidores do canal de ânion de superficíe de plasmódio como agentes antimaláricos
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
CO6251249A2 (es) Un medicamento que comprende un derivado un derivado de carbostirilo y donepezilo para tratar enfermedad de alzheimer
CR9425A (es) Asociacion entre la ferroquina y un derivado de artemisinina para el tratamiento del paludismo
CR20140005A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
ES2662376T3 (es) Dispositivo de asistencia respiratoria para nadadores
AR062401A1 (es) Uso de derivados del 2,5-dihidroxibenceno para tratar dermatitis

Legal Events

Date Code Title Description
FB Suspension of granting procedure